BioAge reports Q3 2026 results, updates timelines for BGE-102 trialsNov 5Quarterly updateBioAge Labs, Inc.
BioAge Labs doses first patient in Phase 2 trial of BGE-102 for diabetic macular edemaOct 2Clinical readoutBioAge Labs, Inc.
BioAge Labs registers Phase 2 study of oral BGE-102 in diabetic macular edemaSep 10Trial updateBioAge Labs, Inc.
BioAge reports Q2 2026 results, first patient dosed in Phase 2 QUELL-CV trialAug 5Quarterly updateBioAge Labs, Inc.